Literature DB >> 1534836

Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome.

M L Freimer1, J D Glass, V Chaudhry, W R Tyor, D R Cornblath, J W Griffin, R W Kuncl.   

Abstract

Eosinophilia-myalgia syndrome (EMS) is a newly described syndrome associated with use of L-tryptophan. A neuropathy with features of axonal degeneration has also been described in conjunction with EMS. Demyelinating polyneuropathy is not a well recognised association of the syndrome. The two patients with EMS reported presented with profound weakness and sensory loss and were found to have clinical, electrophysiological and pathological evidence of a chronic demyelinating polyneuropathy. The concurrence of this neuropathy with EMS, as well as several other features of their illness, is suggestive of an immune mediated mechanism in the pathophysiology of EMS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534836      PMCID: PMC489074          DOI: 10.1136/jnnp.55.5.352

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

1.  High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study.

Authors:  P A van Doorn; A Brand; P F Strengers; J Meulstee; M Vermeulen
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

2.  Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan.

Authors:  P A Hertzman; W L Blevins; J Mayer; B Greenfield; M Ting; G J Gleich
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

Review 3.  The histopathology of Sjögren's syndrome in labial salivary gland biopsies.

Authors:  J S Greenspan; T E Daniels; N Talal; R A Sylvester
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1974-02

Review 4.  Immune mechanisms in inflammatory polyneuropathy.

Authors:  H P Hartung; K Heininger; B Schäfer; W Fierz; K V Toyka
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  P Gajdos; H Outin; D Elkharrat; D Brunel; P de Rohan-Chabot; J C Raphael; M Goulon; C Goulon-Goeau; E Morel
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

6.  Neurotoxicity of human eosinophils.

Authors:  D T Durack; S M Sumi; S J Klebanoff
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

7.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

Authors:  A Pestronk; D R Cornblath; A A Ilyas; H Baba; R H Quarles; J W Griffin; K Alderson; R N Adams
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

8.  Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion.

Authors:  B E Smith; P J Dyck
Journal:  Neurology       Date:  1990-07       Impact factor: 9.910

9.  Conduction block and denervation in Guillain-Barré polyneuropathy.

Authors:  W F Brown; T E Feasby
Journal:  Brain       Date:  1984-03       Impact factor: 13.501

10.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

Authors:  E A Belongia; C W Hedberg; G J Gleich; K E White; A N Mayeno; D A Loegering; S L Dunnette; P L Pirie; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.